Biosimilar pegfilgrastim regulatory update

Mylan and Biocon said EMA accepted for review an MAA for a biosimilar of Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) to treat chemotherapy-induced neutropenia. Neulas...